Abstract
TPS237 Background: Angiogenesis inhibitors have demonstrated significant clinical efficacy in mRCC. Pazopanib and sunitinib are both oral tyrosine kinase inhibitors primarily of VEGFR (−1, −2, and ...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
